"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
Descriptor ID |
D003841
|
MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 7 | 1 | 8 |
1996 | 2 | 1 | 3 |
1997 | 2 | 1 | 3 |
1998 | 2 | 1 | 3 |
1999 | 5 | 0 | 5 |
2000 | 5 | 2 | 7 |
2001 | 12 | 4 | 16 |
2002 | 15 | 0 | 15 |
2003 | 18 | 0 | 18 |
2004 | 16 | 0 | 16 |
2005 | 11 | 9 | 20 |
2006 | 14 | 18 | 32 |
2007 | 11 | 16 | 27 |
2008 | 14 | 23 | 37 |
2009 | 10 | 22 | 32 |
2010 | 11 | 19 | 30 |
2011 | 8 | 25 | 33 |
2012 | 6 | 22 | 28 |
2013 | 9 | 17 | 26 |
2014 | 10 | 21 | 31 |
2015 | 11 | 7 | 18 |
2016 | 10 | 10 | 20 |
2017 | 7 | 14 | 21 |
2018 | 11 | 15 | 26 |
2019 | 5 | 11 | 16 |
2020 | 6 | 8 | 14 |
2021 | 4 | 8 | 12 |
2022 | 1 | 6 | 7 |
2023 | 0 | 6 | 6 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
-
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024 Feb; 21(2):101-124.
-
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
-
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.
-
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6558-6566.
-
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Cell Rep Med. 2023 04 18; 4(4):101013.
-
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer. 2023 05 15; 129(10):1537-1546.
-
Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15. Anticancer Res. 2022 Oct; 42(10):4679-4687.
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
-
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):453.e19-453.e26.